Category: Interviews

In this interview, Boyang Wang of Immortal Dragons discusses the kinds of projects he wants to fund, ways in which the industry can be encouraged to develop, relationships between the East and West in longevity research and development, and what got him involved in longevity. Hello, and welcome to this Lifespan interview, where today, I...

On its website, Rejuve.AI, a company co-founded by its dynamic CEO, Jasmine Smith, and a renowned AI researcher, Ben Goertzel, promises a lot of things: to “democratize longevity, globally,” to enable you to “take control of your data, and harness its earning potential,” and to “unite against aging.” We have been following the company for...

Michael Levin, professor at Tufts University and director of Allen Discovery Center, has been working for years on how bioelectrical patterns affect development and aging. His research proves that this often-overlooked part of biology is immensely important and that mastering its mechanisms might one day do wonders for human health and longevity. By manipulating ion...

Like many people, I’m both wary of and intrigued by people who make bombastic claims. Years in the longevity field have taught me caution but also that big claims are not necessarily outlandish, and few people make bigger claims than Joshua “Scotch” McClure, founder and CEO of Maxwell Biosciences. The company developed Claromers™, synthetic small...

Some longevity biotech companies fit neatly into one of the big buckets we have in this field, like senolytics or cellular reprogramming. Others, such as Junevity, a small spin-out from the University of California, San Francisco, dare to walk an unbeaten path. Junevity pursues the ambitious goal of fixing age-related transcriptional dysregulation using short interfering...

Dr. Marco Quarta runs one of the most interesting start-ups in the longevity field: Rubedo, which focuses on utilizing the senolytic approach to cellular senescence. This company has developed ingenious ways to cope with the notorious heterogeneity of senescent cells and is one of the first to bring its senolytic drug candidate into clinical trials....